European and U.S. aircraft development strategies

A comparison of 20 years of aircraft production in Europe and America. U.S. cost increases in the system acquisition process have resulted in large part from unforeseen (sometimes unforseeable) engineering difficulties in the development phase, and from substantial production commitment before development was complete. Common European strategy completed basic development before beginning production and demonstrated utility through prototypes, using early proof-testing of engines, electronics and airframes. An alternative acquisition strategy to that used in the 1960s in the United States is recommended for the next decade: (1) incremental acquisition, based on a sequence of decision points and a succession of development and production phases; and (2) pronounced austerity in early development phases. These changes would result in lessened cost growth and lower U.S. acquisition costs, as well as in improved predictability of schedule and system performance outcomes.The following statement was prepared for the Committee on Armed Services, United States Senate, and was presented on December 7, 1971.     

What We Have Learned About Teaching Multiparty Negotiation

This article grows out of our experience teaching an advanced course on multiparty negotiation. The main question underlying the course is: “How can experts in two‐party negotiations make themselves effective multiparty negotiators?” In this article, we describe what and how we taught, what we think worked, and what we decided to change after the first year of teaching.     

Interaction of butorphanol, with monoamine oxidase inhibitor, tranylcypromine.

This investigation examines the possibility of interaction between tranylcypromine and butorphanol in comparison to pethidine. The LD50 of pethidine and butorphanol were determined in mice pretreated with the non-selective monoamine oxidase (MAO) inhibitor, tranylcypromine orally for 8 days or with oral saline solution. Tranylcypromine decreased the LD50 of both pethidine and butorphanol by 78% and 41%, respectively. Anesthetized rabbits with halothane pretreated with tranylcypromine or saline were given pethidine (5 mg/kg i.v.) or butorphanol (0.5, 1 and 2 mg/kg i.v.). Pethidine produced a marked increase in blood pressure in rabbits pretreated with tranylcypromine and did not affect significantly the heart rate. Butorphanol did not affect either blood pressure or heart rate at doses of 0.5 or 1 mg/kg. However, the largest dose of butorphanol (2 mg/kg) produced hypotension and tachycardia in rabbits pretreated with tranylcypromine. Neither pethidine nor butorphanol affected the temperature of anesthetized rabbits pretreated with tranylcypromine or saline.     

Developmental Validation of the Quantifiler® Duo DNA Quantification Kit for Simultaneous Quantification of Total Human and Human Male DNA and Detection of PCR Inhibitors in Biological Samples*

Abstract: The Quantifiler^® Duo DNA Quantification kit enables simultaneous quantification of human DNA and human male DNA as well as detection of inhibitors of PCR in a single real-time PCR well. Pooled human male genomic DNA is used to generate standard curves for both human (ribonuclease P RNA component H1) and human male (sex determining region Y) specific targets. A shift in the cycle threshold (C_T) values for the internal positive control monitors the presence of PCR inhibitors in a sample. The assay is human specific and exhibits a high dynamic range from 0.023 to 50 ng/μL. In addition, the multiplex assay can detect as little as 25 pg/μL of human male DNA in the presence of a 1000-fold excess of human female DNA. The multiplex assay provides assessment of the DNA extract and guidance for the selection of the appropriate AmpFℓSTR^® Amplification Kit to obtain interpretable short tandem repeat profiles.